Next Article in Journal
In Vitro Gastrointestinal Digestion and Colonic Fermentation of High Dietary Fiber and Antioxidant-Rich Mango (Mangifera indica L.) “Ataulfo”-Based Fruit Bars
Next Article in Special Issue
A Dietary Intervention of Bioactive Enriched Foods Aimed at Adults at Risk of Metabolic Syndrome: Protocol and Results from PATHWAY-27 Pilot Study
Previous Article in Journal
Skipping Breakfast and a Meal at School: Its Correlates in Adiposity Context. Report from the ABC of Healthy Eating Study of Polish Teenagers
Previous Article in Special Issue
Guava (Psidium guajava) Fruit Extract Prepared by Supercritical CO2 Extraction Inhibits Intestinal Glucose Resorption in a Double-Blind, Randomized Clinical Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Nutrients
Volume 11
Issue 7
10.3390/nu11071565
nutrients-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review

by
Sanne Verhoog
1,*,
Petek Eylul Taneri
2,
Zayne M. Roa Díaz
1,
Pedro Marques-Vidal
3,
John P. Troup
4,
Lia Bally
5,
Oscar H. Franco
1,
Marija Glisic
6 and
Taulant Muka
1
1
Institute of Social and Preventive Medicine, University of Bern, 3012 Bern, Switzerland
2
Corlu Cancer Early Diognosis and Training Center, 59100 Tekirdag, Turkey
3
Department of Medicine, Internal Medicine, Lausanne University Hospital (CHUV), 1011 Lausanne, Switzerland
4
Standard Process Inc Nutrition Innovation Center, Kannapolis, NC 28018, USA
5
Department of Diabetes, Endocrinology, Clinical Nutrition and Metabolism, Bern University Hospital, 3010 Bern, Switzerland
6
Leibniz Institute for Prevention Research and Epidemiology-BIPS, 28359 Bremen, Germany
*
Author to whom correspondence should be addressed.
Nutrients 2019, 11(7), 1565; https://doi.org/10.3390/nu11071565
Original submission received: 6 June 2019 / Revised: 5 July 2019 / Accepted: 8 July 2019 / Published: 11 July 2019
(This article belongs to the Special Issue Dietary Bioactives and Human Health)
Browse Figure
Review Reports Versions Notes

Abstract

:
Akkermansia muciniphila and Faecalibacterium prausnitzii are highly abundant human gut microbes in healthy individuals, and reduced levels are associated with inflammation and alterations of metabolic processes involved in the development of type 2 diabetes. Dietary factors can influence the abundance of A. muciniphila and F. prausnitzii, but the evidence is not clear. We systematically searched PubMed and Embase to identify clinical trials investigating any dietary intervention in relation to A. muciniphila and F. prausnitzii. Overall, 29 unique trials were included, of which five examined A. muciniphila, 19 examined F. prausnitzii, and six examined both, in a total of 1444 participants. A caloric restriction diet and supplementation with pomegranate extract, resveratrol, polydextrose, yeast fermentate, sodium butyrate, and inulin increased the abundance of A. muciniphila, while a diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols decreased the abundance of A. muciniphila. For F. prausnitzii, the main studied intervention was prebiotics (e.g. fructo-oligosaccharides, inulin type fructans, raffinose); seven studies reported an increase after prebiotic intervention, while two studies reported a decrease, and four studies reported no difference. Current evidence suggests that some dietary factors may influence the abundance of A. muciniphila and F. prausnitzii. However, more research is needed to support these microflora strains as targets of microbiome shifts with dietary intervention and their use as medical nutrition therapy in prevention and management of chronic disease.

1. Introduction

The gut microbiota, defined as the complex, diverse, and vast microbial community resided in the human gut, is emerging as a key player in the pathophysiology of several chronic conditions [1]. Gut microbiota extract energy from nutrients and regulate several biological processes. A microbiota imbalance, such as low abundance of Akkermansia muciniphila and Faecalibacterium prausnitzii, favours inflammatory processes, potentially leading to inflammatory disorders of the gastrointestinal tract such as irritable bowel syndrome and inflammatory bowel disease, as well as to colorectal cancer [2,3,4,5,6]. Also, increases in A. muciniphila and F. prausnitzii abundance can regulate metabolic functions and appear to exert protective effects against the development of obesity [7], type 2 diabetes (T2D) [8], and atherosclerosis [9]. Therefore, these two bacteria have been considered as potential bioindicators of human cardiometabolic health and conditions where underlying inflammation plays a role. A. muciniphila is a mucin-degrading bacterium of the phylum Verrucomicrobia, while F. prausnitzii is an important butyrate-producer of the phylum of Firmicutes. F. prausnitzii is also the major bacterium of the Clostridium leptum group [10,11]. It accounts for 5% of total bacteria in faeces and it is an important source of energy for the colonocytes [12,13].
Modulating the abundance of A. muciniphila and F. prausnitzii in the intestinal flora may contribute to prevent and treat inflammatory and cardiometabolic diseases [14,15,16]. Studies have shown that dietary factors can influence the diversity and composition of the gut microbiome more than human genetic factors [17]. Data from animal studies suggest that polyphenols-rich diets and specific phytochemicals such as curcumin and epigallocatechin gallate may improve the abundance of A. muciniphila and F. prausnitzii in the gut microbiome [18,19,20,21,22]. A clinical trial with obese insulin-resistant patients showed that resveratrol, a natural phenol, increased the abundance of A. muciniphila in Caucasians but not in other ethnic groups [23]. A diet high in fermentable oligo-, di- and monosaccharides and polyphenols (FODMAP), which has been implicated in digestive diseases such as irritable bowel syndrome, inflammatory bowel disease, and Crohn’s disease, resulted in changes in gut microbiota including changes in A. muciniphila and F. prausnitzii but the evidence is not consistent [24,25]. Furthermore, intake of dietary fibres, such as the soluble fibre inulin, has been associated with increased abundance of A. muciniphila and F. prausnitzii in healthy and overweight/obese individuals, but another study showed no influence of inulin intake on F. prausnitzii [26,27,28]. Despite the emerging evidence of the impact of dietary factors on changing the microbiome composition, a comprehensive assessment of the dietary interventions in modulating A. muciniphila and F. prausnitzii is lacking. Identifying dietary microbiome modulators may help understanding how diet and phytochemicals can be employed in medical nutrition therapy to increase the abundance of A. muciniphila and F. prausnitzii.
Therefore, the aim of this systematic review is to identify, integrate and discuss all available evidence from clinical trials in humans on the association of diet with changes in A. muciniphila and F. prausnitzii.

2. Material and Methods

2.1. Literature Search

This review was conducted and reported in accordance with the PRISMA [29] and MOOSE [30] guidelines (Tables S1 and S2). PubMed and Embase were used to identify published studies from database inception until April 23, 2019 (date last searched) that examined the associations between any dietary factor and changes in A. muciniphila and F. prausnitzii in humans. To capture all relevant studies, we used a broad search strategy using terms related to A. muciniphila and F. prausnitzii (Appendix A). We did not apply any restrictions with regard to language and date. Furthermore, to identify additional relevant studies, we checked the reference lists of the studies included in the current review.

2.2. Study Selection Criteria

To be included in the review, studies had to full-fill all of the following criteria: (i) were clinical trials (randomized placebo-controlled trials, randomized trials comparing different exposures and single-arm trials); (ii) included subjects 18+ years, and (iii) reported associations between any dietary intervention and absolute and relative abundance of A. muciniphila, or F. prausnitzii, or both. As we were interested to understand the effect of dietary factors on gut microbiome, we decided to include all trials irrespective of their aim; therefore, all eligible trials that reported baseline and end of study information on outcomes of interest were included in this review. Studies conducted in animals, children/teenagers, conference abstracts, letters to the editor, interventions examining probiotics solely and non-interventional studies were excluded. Following the selection criteria, two reviewers independently screened titles and abstracts for eligibility. Next, two reviewers assessed the full-text of potentially eligible studies. In cases of disagreement, a decision was made by consensus or, if necessary, a third reviewer was consulted.

2.3. Data Extraction

Two reviewers extracted the data independently using a predesigned form including study design, study population, location, age range, dietary intervention and control (if applicable), duration of intervention and study results.

2.4. Assessing the Quality of Trials

Two reviewers evaluated the risk of bias within each study using “The Cochrane Collaboration’s tool” [31]. Studies were judged to be at low or high risk of bias based on criteria to evaluate random sequence generation, allocation concealment, blinding of participants/personnel and outcome assessment, incomplete outcome data and selective reporting. Trials were considered to be in low risk of bias if allocation concealment, blinding of participants and outcome assessors were all coded “yes”, if a compliance assessment was done and the number of dropouts and reasons for dropout were reported; otherwise, the trials were considered to be at high risk of bias. If the risk of bias could not be determined in any of the segments, (e.g., information not provided) the risk of bias was classified as unknown. Lastly, for each trial, an overall score of quality was provided. Good quality was assigned when all criteria were met (i.e. low risk of bias for each domain). Fair quality was assigned when one criterion was not met (i.e. high risk of bias for one domain) or two criteria were unclear, and the assessment that this was unlikely to have biased the outcome, and there is no known important limitation that could invalidate the results. Poor quality was assigned when (i) one criterion was not met or two criteria were unclear, and the assessment that this was likely to have biased the outcome, and there are important limitations that could invalidate the results, or (ii) when two or more criteria were listed as high or unclear risk of bias.

3. Results

3.1. Study Identification and Selection

In total, we identified 1433 relevant citations. After screening based on titles and abstracts, 59 citations were selected for detailed full text evaluation. Of those, 30 articles [23,24,25,26,27,28,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55], based on 29 unique trials, met the selection criteria and were included in the review (Figure 1). Among these, 19 articles examined F. prausnitzii [26,27,32,34,36,37,38,39,41,42,44,46,47,49,50,51,52,54,55], five articles examined A. muciniphila [23,28,35,43,48], and six articles examined both [24,25,33,40,45,53].

3.2. Characteristics of the Included Trials

Of the 29 unique included trials, 15 were conducted in Europe, 8 in North America, 4 in Australia and New Zealand, 1 in Iran, and 1 in China; 22 were conducted among both men and women, 4 among men and 3 among women. Overall, the trials reported results for 1444 participants. All trials were published after 2005 and 80 percent in the last 5 years. The baseline age of the participants was 18+. The duration of the interventions ranged from 2 weeks to 6 months. The design of the included trials comprised randomized double-blind placebo-controlled trials, single-arm trials, multi-arm parallel trials, cross-over trials, and single and multi-centre trials. Detailed characteristics of the included trials are presented in Table 1 and Table 2. Two trials scored an overall good quality score, indicating a low risk of bias in all domains (Table S3), whereas for the other trials the overall score was fair (n = 10) or poor (n = 18). There was a low risk of bias for all trials in the domain sequence generation and allocation concealment. For five trials, the risk of bias in the domain blinding of participants and personnel was unclear. In the domain blinding of assessment, 16 trials had an unclear risk of bias, as this was not clearly stated in these trials. Nine trials did not report how they handled missing data, and were therefore classified as being unclear in the assessment of risk of bias in the domain of missing data. High risk of bias was found in the domain of selective reporting for 14 trials, as they did not report effect estimates. The domain “other bias” included the risk of false positive findings for 14 trials, as these trials did not account for multiple testing in their analysis.

3.3. Trials Examining A. muciniphila

Eleven trials examined the association between a dietary intervention and A. muciniphila [23,24,25,28,33,35,40,43,45,48,53]. The dietary interventions examined were a caloric restriction diet, a reduced energy diet, a diet low in fermentable oligo-, di-, mono-saccharides and polyols (FODMAP), supplemental fibres, a yeast fermentate (EpiCor), sodium butyrare and inulin, pomegranate extract, kiwifruit capsules, and resveratrol. Findings are summarized in Table 1.
Dao M et al. evaluated a caloric restriction diet compared to a weight stabilization diet among overweight and obese participants [35]. In the caloric restricted group, the abundance of A. muciniphila decreased in participants with a high baseline level of A. muciniphila and increased in participants with low A. muciniphila levels. In the weight stabilization diet group, the abundance of A. muciniphila decreased in participants with both low and high baseline levels of A. muciniphila. Similarly to Dao M et al. [13], Medina-Vera I et al. examined a reduced energy diet compared to placebo in patients with T2D [45]. They reported that consumption of the reduced-energy diet increased levels of A. muciniphila by approximately 125%. However, two other studies coming from the same cross-over trial examined a diet low in FODMAPs compared to a typical Australian diet containing FODMAPs, and showed that the typical Australian diet increased absolute and relative abundance of A. muciniphila [24,25].
A cross-over trial conducted showed that polydextrose supplementation increased A. muciniphila compared to soluble corn fibre supplementation or placebo (i.e. no supplemental fibre control) among healthy individuals [40]. Another cross-over trial reported no changes in relative or absolute abundance of A. muciniphila after increasing the intake of resistant starch and wheat bran foods among healthy individuals and patients with ulcerative colitis in remission [53]. Supplementation with EpiCor, a yeast fermentate, increased A. muciniphila compared to placebo (maltodextrin) in healthy individuals with moderate symptoms of gastrointestinal discomfort [48]. Supplementation with sodium butyrate or inulin increased A. muciniphila compared to placebo (starch) in overweight and obese diabetic patients, but no significant differences were found with combined sodium butyrate and inulin supplementation [28].
Pomegranate extract increased A. muciniphila by 47-fold in healthy metabolite urolithin A producers compared to non-producers [43]. However, kiwifruit capsules did not have a significant effect on A. muciniphila abundance in healthy and functionally constipated individuals [33]. Resveratrol supplementation led to an increase in A. muciniphila in USA Caucasians, but not in other ethnic groups [23].

3.4. Trials Examining F. prausnitzii

Twenty-five studies examined the effect of dietary interventions on F. prausnitzii [24,25,26,27,32,33,34,36,37,38,39,40,41,42,44,45,46,47,49,50,51,52,53,54,55]. Of these 25 studies, 17 studies examined prebiotics and the other studies examined isoflavones, dietary fat, carbohydrates, a ketogenic diet, kiwifruit capsules, sun-dried raisins, iron therapy, and a Chinese herbal formula. The findings are summarized in Table 2.
Treatment with prebiotic inulin-type fructans led to an increase of F. prausnitzii compared to placebo (maltodextrin) in obese women [36]. Supplementation of fructo-oligosaccharides, which are prebiotic fructans, increased the level of F. prausnitzii compared to placebo (maltodextrin) in patients with diarrhoea or mixed irritated bowel syndrome [41]. Supplementation of prebiotic inulin-oligofructose also increased the level of F. prausnitzii in healthy individuals [26]. Moreno-Indias I. et al. studied the prebiotic effect of red wine in male metabolic syndrome patients and healthy individuals and reported an increase of F. prausnitzii for red wine intake compared to baseline [46]. Another study found that F. prausnitzii was greater when healthy men consumed polydextrose or soluble corn fiber supplementation, which could be potential prebiotics, than when they consumed no supplemental fiber [40]. Medina-Vera I. et al. examined the effect of a reduced energy diet with prebiotic properties compared to a placebo diet in patients with type 2 diabetes, and reported an increase of F. prausnitzii of 34% [45]. Fernando WMU et al. studied the prebiotic potential of chickpea oligosaccharides (raffinose) alone or as components of chickpea and found that F. prausnitzii was more abundant in the raffinose diet and the chickpea diet compared to the control diet [38]. Ingestion of butyrylated high amylose maize starch led to greater relative increases of F. prausnitzii compared to ingestion of low amylose maize starch [55].
However, there are also studies reporting a decrease in F. prausnitzii after a prebiotic intervention. Patients from the intensive care unit starting nasogastric enteral nutrition receiving additional oligofructose/inulin had significantly lower concentration of F. prausnitzii compared to patients receiving placebo [44]. A combination of epigallocatechin-3-gallate and resveratrol decreased F. prausnitzii compared to placebo in obese men but not in obese women [47]. A cross-over trial comparing a fibre-free enteral formula or a formula supplemented with dietary fibre consisting of pea fibre and fructo-oligosaccharides showed large reductions in the number of F. prausnitzii during both the fibre-free and fibre-supplemented diets among healthy participants [52].
Moreover, some studies reported no differences in F. prausnitzii after a prebiotic intervention. Halmos E. et al. examined a diet low in FODMAPs compared to a diet containing FODMAPs in two different studies in patients with irritated bowel syndrome and patients with clinically quiescent Crohn’s disease [24,25]. They did not report significant differences in F. prausnitzii between the diets in both studies. Another study conducted among men with Crohn’s disease examining the effect of fructo-oligosaccharides compared to a non-prebiotic carbohydrate also did not found differences in F. prausnitzii [32]. Vulevic J. et al. investigated the effect of administering Bi2muno (B-GOS) compared to placebo (maltodextrin) in a cross-over trial among overweight subjects predisposed to the development of metabolic syndrome, and reported no significant effects on counts of the F. prausnitzii cluster during the study [54]. Increasing the intake of resistant starch and wheat bran foods containing fibres did not change the relative and absolute abundance of F. prausnitzii in healthy participants and patients with ulcerative colitis in remission [53]. Among healthy individuals, Ramnani P. et al. studied the prebiotic effect of Jerusalem artichoke compared to a placebo, but did not report significant differences in F. prausnitzii [27].
Clavel T. et al. studied the effect of a prebiotic (isoflavones and fructo-oligosaccharides) or probiotic (isoflavones and B. animalis DN-173 010) compared to placebo (isoflavones alone) in postmenopausal women [34]. They reported that percentages of F. prausnitzii decreased significantly in control subjects compared to probiotic and prebiotic groups. Guadamuro L. et al. examined the effect of isoflavone concentrate supplementation alone in menopausal women and found an increase in the intensity of F. prausnitzii after isoflavone supplementation [39].
Fava F. et al. showed that the type and quantity of dietary fat and carbohydrate can alter faecal microbiome in individuals at increased risk of metabolic syndrome, whereby F. prausnitzii increased after intervention of a diet with high monounsaturated fatty acids and a high glycaemic index, compared to diets with high saturated fatty acids, high monounsaturated fatty acids in combination with a low glycaemic index, or with high carbohydrates in combination with high or low glycaemic index [37]. A ketogenic diet including a minimum of 0.8-1 gram per kilogram of bodyweight of protein from animal sources did not have an effect on F. prausnitzii [49]. Consumption of kiwifruit capsules increased F. prausnitzii abundance in functionally constipated individuals, compared to placebo [33]. Addition of sun-dried raisins to the diet also increased the abundance of F. prausnitzii among healthy individuals [50]. Oral iron therapy resulted in lower abundance of F. prausnitzii compared to intravenous iron therapy among iron deficient inflammatory bowel disease patients [42]. Xu J et al. examined the effect of a Chinese herbal formula (Gegen Qinlian Decoction) in a low, medium and high dose in recently diagnosed type 2 diabetes patients. They reported that all three doses of Gegen Qinlian Decoction treatment significantly enriched F. prausnitzii compared with baseline [51].

4. Discussion

In the current systematic review of clinical trials, diet-induced changes in A. muciniphila and F. prausnitzii were reviewed. An increase in abundance of A. muciniphila was observed after a caloric restriction diet, supplementation with pomegranate extract, resveratrol, polydextrose, EpiCor or sodium butyrate, whereas a diet low in FODMAPs decreased the abundance of A. muciniphila. Prebiotics use was the main dietary intervention investigated in relation to F. prausnitzii, showing contradictory results depending on the type of prebiotics. Isoflavone supplementation and intake of some types of fatty acids, such as monounsaturated fatty acids, was associated with increased abundance of F. prausnitzii, whereas inulin intake and a reduced energy diet increased the abundance of both A. muciniphila and F. prausnitzii.
Approximately 100 trillion microorganisms are present in the body but mostly residing in the gastrointestinal tract [56]. In response to environmental changes, the gut microbiome can affect gene expression in humans. While around 23,000 genes make up the human genome, the microbiome consists over 3 million genes producing thousands of metabolites, and therefore affecting many aspects of human health, including gastrointestinal and cardiometabolic phenotypes [56,57]. Changes in microbiota are observed in patients with inflammatory gastrointestinal disease, prediabetes, and T2D, particularly a decreased abundance of A. muciniphila and F. prausnitzii [58]. In addition, low abundance of A. muciniphila and F. prausnitzii has been associated with increased inflammatory processes and atherosclerosis, and F. prausnitzii transplantation has been shown to be an effective therapeutic approach for diabetes and its complications [59]. F. prausnitzii is an important butyrate-producer with anti-inflammatory properties, while A. muciniphila degrades mucin in the gut lining resulting in syntrophic interactions and stimulation of intestinal metabolite pool [60]. For example, co-cultivations of A. muciniphila with butyrate-producing bacteria resulted in syntrophic growth and butyrate production [60]. Butyrate plays an important role in anti-inflammation and maintaining intestinal barrier integrity by modulating intestinal macrophages’ function, downregulating lipopolysaccharide-induced pro-inflammatory mediators, such as nitric oxide, IL-6, and IL-12, inducing the differentiation of regulatory T cells and stabilizing hypoxia-inducible factor [61,62,63,64]. Further, butyrate can have beneficial effects on glucose and energy homeostasis by activating intestinal gluconeogenesis, as well as inducing apoptosis of colon cancer cells [65]. Studies in animal models have shown that colonization by A. muciniphila resulted in transcriptional changes, leading to an increase in the expression of genes associated with immune responses and cellular lipid metabolism [11,66]. Besides degrading mucins, A. muciniphila can also stimulate mucin production, suggesting an autocatalytic process [67,68]. Mucins are large, highly glycosylated proteins that play a crucial role in luminal protection of the gastrointestinal tract, thereby reducing translocation of pro-inflammatory lipopolysaccharides, controlling fat storage, adipose tissue metabolism, and glucose homeostasis [68,69]. Therefore, altering the abundance and dynamics of these two strains of bacteria can lead to alterations in metabolic processes, and prevention and management of metabolic diseases.
Diet is the main source of energy to humans, but can also modulate microbiota and impact host-microbe interactions [70]. Therefore, gut microbiota may be crucial in mediating the health effects of foods. The gut microbiota provides the exoenzymes to catalyze and ferment substrates that cannot be completely digested by the human digestive tract to produce metabolites such as short fatty acids including butyrate [71]. Such non-digestible substrates include complex carbohydrates derived from plants and dietary fibres from cereals, legumes, vegetables, fruits, and nuts. Modulation of the gut microbiome through adherence to a high-fibre plant-based diet has been suggested as a potential therapeutic approach for prevention and treatment of inflammatory gastrointestinal diseases and metabolic diseases such as T2D and restoration of microbiota function [72,73]. In line with this hypothesis, we found in the current review that inulin-type fructans, fructo-oligosaccharides, polydextrose or soluble corn fiber supplementation, and raffinose can lead to increase abundance of A. muciniphila and/or F. prausnitzii. However, we found no consistent associations or decreases for other types of prebiotics and abundance of F. prausnitzii such as inulin-oligofructose and resistant starch or wheat bran foods. Yet, this inconsistency is somehow expected considering that studies used different types of prebiotics, for which bacteria have differing specificity and therefore affecting differently the number of fermentable substrates in the gut [14]. In addition, different types of fibres have differing effects in the luminal pH and transit rate. Type of fibre being consumed, gut transit time, and the functional capabilities of gut microbiota influences the fermentation of carbohydrate and subsequent regional delivery of metabolites [14]. Hence, the different results we see in this study on the association between prebiotics and F. prausnitzii may reflect this complexity. This is also in line with the findings from observational studies showing that some types of dietary fibres (such as those from cereals) but not all are associated with reduced risk of T2D [74].
Pomegranate extract, a rich and varied source of polyphenolic compounds, and resveratrol polyphenol have been widely investigated for their antioxidant, anti-inflammatory, anti-diabetic and anti-atherogenic properties in both genders [75,76]. Phytoestrogens seem to have similar effects but mainly in women; use of phytoestrogens in women is associated with improvement of menopausal symptoms, better glycaemic control and reduced risk of T2D [77,78]. However, the mechanisms of action of these compounds remain unclear. Microbiome plays an important role in metabolizing the non-absorbed fraction of these compounds, and therefore defining the ability of these compounds such as polyphenols to exert health effects [79]. On the other hand, pomegranate and polyphenol resveratrol can modulate the abundance of A. muciniphila, while isoflavone phytoestrogens alone, and not in combination with fibres, can modulate the abundance of F. prausnitzii [19,23,34,39,43]. While it is not completely clear how such compounds can affect intestinal microorganisms, limited evidence suggests that it could be either by the selective pressure they exert on specific microorganisms, or by modifying environmental conditions of the intestinal tract [34].
Modifying the diet can lead to rapid changes in microbiota within the first days. A study reported human gut microbiome changes after only 24 hours after shifting between plant and animal protein-based diets [80]. Similarly, the studies included in this review showed that dietary interventions are associated with changes in A. muciniphila and F. prausnitzii in the first weeks of intervention [26,41,44,50]. This suggests that diet may be an important and fast modifier of A. muciniphila and F. prausnitzii, and the microbiome in general, and a promising future therapeutic approach to prevent and treat inflammatory and metabolic conditions associated with specific microbiome strains. Our study highlights several additional factors that might be important to consider for a more comprehensive understanding of diet-related diseases and to elucidate the links between nutrition and dynamics of A. muciniphila and F. prausnitzii. However, dietary effects on microbiome may depend on health status, the baseline abundance of bacteria strains already in the gut, ethnicity, medication, and sex [24,25,32,33,34,35,37,41,42,45,46,51]. This could also explain the inconsistent results across studies in this systematic review, as we included studies among different sexes, ethnicities and health statuses. For instance, men and women have different genetic background, energy and nutritional requirements across the lifespan, as well as differences in gastrointestinal transit time, which can contribute to sex differences in microbiome [81,82]. Therefore, considering the sex-differences in the gut microbiome can provide novel insights in tailoring interventions and treatment, and therefore improving precision medicine. Machine-learning algorithms can help to predict inflammatory metabolic responses to meals, microbiome and how that differs by sex and ethnicity, and thus help to improve the emerging concept of personalized nutrition. For example, Zeevi et al. [83] used a machine-learning algorithm to predict personalised glucose responses after meals based on clinical and gut microbiome data. Based on the algorithm, a dietary intervention was designed and successfully shown to normalize blood glucose levels in a double-blinded randomised crossover trial of 26 patients [83]. Future research based on a large population-based studies and clinical trials is needed to evaluate a greater variety of food components and establish whether such personalised nutritional approaches based on microbiome composition are feasible and can improve clinical outcomes.
Further, it may be important to understand the differences that whole foods and ultra-processed foods may have on gut microbiota and subsequently on health outcomes. It has been shown that fibre-rich ultra-processed foods change the microbiota towards a less diverse and less beneficial composition compared to fibre-rich whole foods [84]. Processed foods have been undergone high heat and pressure, which can lead to several chemical and physical changes, including inactivation of endogenous enzymes, increased content of soluble dietary fibre and mechanical damage to the cell walls [85]. This suggests that whole unprocessed foods will enter the colon in an intact state which could favour the growth of bacteria that degrade fibre and produce beneficial metabolites, and thus exerting protective effects on health outcomes [85]. This theory is also supported from epidemiological studies showing that whole foods such as whole fish and whole grains can have a more beneficial effect than processed fish and refined grains, and that processed meat is in general associated with a stronger adverse health effect than whole meat [86]. Therefore, investigating the health effects of nutrients present in ultra-processed and whole food in the context of the microbiome can shed light on the mechanisms of the adverse effects of the Western diet.
To our knowledge, this is the first systematic review on the subject that critically and systematically appraised the literature on the effect of dietary interventions on A. muciniphila and F. prausnitzii. Nevertheless, some limitations from the included studies in this review merit careful consideration. Firstly, not all studies reported baseline and/or end of trial estimates between groups, and therefore the interpretation and the strength of the reported associations remained unclear. This and other factors (such as different types of study populations, interventions, and study designs) also limited providing a meaningful quantitative pooling of the existing data. It is important that future studies report summary estimates for all bacteria strains under investigation, and not apply selective reporting. Further, the studies included in this review were of suboptimal quality and the conclusions should be interpreted with caution. Most studies have been published in recent years and were conducted in limited sample sizes (16 studies had ≤30 participants) within interventions lasting short time periods (15 studies lasted for ≤6 weeks). Moreover, we cannot exclude the possibility that the changes we observed in A. muciniphila and F. prausnitzii are due to changes that dietary factors can lead to in the health condition of the participants, rather than the effect of diet alone. Nevertheless, most of clinical trials included in this review were performed in healthy individuals, and therefore we would expect that it is less likely that dietary factors we examined alter the abundances of the bacteria strains through changes in health. We also cannot exclude the possibility that the dietary factors lead to changes in other bacterial strains, which might have an effect on A. muciniphila and F. prausnitzii. What appears to be a promising field for intervention to improve health is also highly complex and new studies are required to untangle these complex interactions of diet, microbiome, and diseases in larger populations.

5. Conclusions

In summary, we found that specific dietary interventions could influence the abundance of A. muciniphila and F. prausnitzii, highlighting a novel potential mechanism describing how diet can affect inflammatory and metabolic health outcomes. Understanding the links between different types of dietary interventions and changes in abundance of A. muciniphila and F. prausnitzii can help shaping future nutritional recommendations and designing medical nutrition therapies that can help prevent and treat diseases related to these two strains of bacteria such as inflammatory gastrointestinal disease and T2D.

Supplementary Materials

The following are available online at https://www.mdpi.com/2072-6643/11/7/1565/s1, Table S1: PRISMA 2009 checklist, Table S2: MOOSE checklist, Table S3: The Cochrane Collaboration’s tool for assessing risk of bias.

Author Contributions

O.H.F. and T.M. designed and conceived the study. S.V., P.E.T., Z.M.R.D., M.G. and T.M. screened title/abstract, obtained full text, determined eligibility of articles and participated in data extraction. S.V., P.E.T., Z.M.R.D., P.M.-V., J.P.T., L.B., M.G., O.H.F. and T.M. participated in data synthesis/analysis and interpretation of the data. SV and TM drafted the final manuscript. S.V. and T.M. had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. All authors contributed to the critical revision of the manuscript and approved the final version.

Funding

O.H.F. reported receiving grants or research support from Metagenics Inc. T.M. reported receiving personal fees from Standard Process.

Conflicts of Interest

The authors declare no conflict of interest.

Appendix A

Search Strategy

PUBMED 384

(akkermansia[All Fields] AND muciniphila[All Fields]) OR (“faecalibacterium prausnitzii”[MeSH Terms] OR (“faecalibacterium”[All Fields] AND “prausnitzii”[All Fields]) OR “faecalibacterium prausnitzii”[All Fields]) AND “humans”[MeSH Terms].

EMBASE 1049

((‘akkermansia muciniphila*’: ab, ti OR ‘faecalibacterium prausnitzii*’: ab, ti) OR (‘akkermansia muciniphila’/exp OR ‘faecalibacterium prausnitzii’/exp)) AND ‘human’/de.

References

  1. Cho, I.; Blaser, M.J. The human microbiome: At the interface of health and disease. Nat. Rev. Genet. 2012, 13, 260. [Google Scholar] [CrossRef] [PubMed]
  2. Cao, Y.; Shen, J.; Ran, Z.H. Association between Faecalibacterium prausnitzii Reduction and Inflammatory Bowel Disease: A Meta-Analysis and Systematic Review of the Literature. Gastroenterol. Res. Pract. 2014, 2014, 872725. [Google Scholar] [CrossRef] [PubMed]
  3. Davies, N.K.; O’Sullivan, J.M.; Plank, L.D.; Murphy, R. Altered gut microbiome after bariatric surgery and its association with metabolic benefits: A systematic review. Surg. Obes. Relat. Dis. Off. J. Am. Soc. Bariatr. Surg. 2019, 15, 656–665. [Google Scholar] [CrossRef] [PubMed]
  4. Ferreira-Halder, C.V.; Faria, A.V.S.; Andrade, S.S. Action and function of Faecalibacterium prausnitzii in health and disease. Best Pract. Res. Clin. Gastroenterol. 2017, 31, 643–648. [Google Scholar] [CrossRef] [PubMed]
  5. Geerlings, S.Y.; Kostopoulos, I.; de Vos, W.M.; Belzer, C. Akkermansia muciniphila in the Human Gastrointestinal Tract: When, Where, and How? Microorganisms 2018, 6, 75. [Google Scholar] [CrossRef]
  6. Lopez-Siles, M.; Martinez-Medina, M.; Surís-Valls, R.; Aldeguer, X.; Sabat-Mir, M.; Duncan, S.H.; Flint, H.J.; Garcia-Gil, L.J. Changes in the Abundance of Faecalibacterium prausnitzii Phylogroups I and II in the Intestinal Mucosa of Inflammatory Bowel Disease and Patients with Colorectal Cancer. Inflamm. Bowel Dis. 2016, 22, 28–41. [Google Scholar] [CrossRef] [PubMed][Green Version]
  7. Gao, Z.; Yin, J.; Zhang, J.; Ward, R.E.; Martin, R.J.; Lefevre, M.; Cefalu, W.T.; Ye, J. Butyrate improves insulin sensitivity and increases energy expenditure in mice. Diabetes 2009, 58, 1509–1517. [Google Scholar] [CrossRef]
  8. de Goffau, M.C.; Luopajarvi, K.; Knip, M.; Ilonen, J.; Ruohtula, T.; Härkönen, T.; Orivuori, L.; Hakala, S.; Welling, G.W.; Harmsen, H.J.; et al. Fecal microbiota composition differs between children with beta-cell autoimmunity and those without. Diabetes 2013, 62, 1238–1244. [Google Scholar] [CrossRef]
  9. Li, J.; Lin, S.; Vanhoutte, P.P.; Woo, C.C.; Xu, A. Akkermansia Muciniphila Protects Against Atherosclerosis by Preventing Metabolic Endotoxemia-Induced Inflammation in Apoe-/- Mice. Circulation 2016, 133, 2434–2446. [Google Scholar] [CrossRef]
  10. Derrien, M.; Vaughan, E.E.; Plugge, C.C.; de Vos, W.M. Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int. J. Syst. Evol. Microbiol. 2004, 54 Pt 5, 1469–1476. [Google Scholar] [CrossRef][Green Version]
  11. Derrien, M.; Van Baarlen, P.; Hooiveld, G.; Norin, E.; Muller, M.; de Vos, W.M. Modulation of Mucosal Immune Response, Tolerance, and Proliferation in Mice Colonized by the Mucin-Degrader Akkermansia muciniphila. Front. Microbiol. 2011, 2, 166. [Google Scholar] [CrossRef][Green Version]
  12. Arumugam, M.; Raes, J.; Pelletier, E.; Le Paslier, D.; Yamada, T.; Mende, D.R.; Fernandes, G.R.; Tap, J.; Bruls, T.; Batto, J.M.; et al. Enterotypes of the human gut microbiome. Nature 2011, 473, 174–180. [Google Scholar] [CrossRef]
  13. Louis, P.; Young, P.; Holtrop, G.; Flint, H.H. Diversity of human colonic butyrate-producing bacteria revealed by analysis of the butyryl-CoA:acetate CoA-transferase gene. Environ. Microbiol 2010, 12, 304–314. [Google Scholar] [CrossRef]
  14. Ganesan, K.; Chung, S.S.; Vanamala, J.; Xu, B. Causal Relationship between Diet-Induced Gut Microbiota Changes and Diabetes: A Novel Strategy to Transplant Faecalibacterium prausnitzii in Preventing Diabetes. Int. J. Mol. Sci. 2018, 19, 3720. [Google Scholar] [CrossRef]
  15. Schneeberger, M.; Everard, A.; Gomez-Valades, A.G.; Matamoros, S.; Ramírez, S.; Delzenne, N.M.; Gomis, R.; Claret, M.; Cani, P.D. Akkermansia muciniphila inversely correlates with the onset of inflammation, altered adipose tissue metabolism and metabolic disorders during obesity in mice. Sci. Rep. 2015, 5, 16643. [Google Scholar] [CrossRef]
  16. Sokol, H.; Pigneur, B.; Watterlot, L.; Lakhdari, O.; Bermúdez-Humarán, L.G.; Gratadoux, J.J.; Blugeon, S.; Bridonneau, C.; Furet, J.P.; Corthier, G.; et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. USA 2008, 105, 16731–16736. [Google Scholar] [CrossRef]
  17. De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poullet, J.B.; Massart, S.; Collini, S.; Pieraccini, G.; Lionetti, P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc. Natl. Acad. Sci. USA 2010, 107, 14691–14696. [Google Scholar] [CrossRef][Green Version]
  18. Ejtahed, H.H.; Soroush, A.A.; Siadat, S.S.; Hoseini-Tavassol, Z.; Larijani, B.; Hasani-Ranjbar, S. Targeting obesity management through gut microbiota modulation by herbal products: A systematic review. Complement. Ther. Med. 2019, 42, 184–204. [Google Scholar] [CrossRef]
  19. Anhe, F.F.; Pilon, G.; Roy, D.; Desjardins, Y.; Levy, E.; Marette, A. Triggering Akkermansia with dietary polyphenols: A new weapon to combat the metabolic syndrome? Gut Microbes 2016, 7, 146–153. [Google Scholar] [CrossRef]
  20. Jang, S.; Sun, J.; Chen, P.; Lakshman, S.; Molokin, A.; Harnly, J.M.; Vinyard, B.T.; Urban J.F., Jr.; Davis, C.D.; Solano-Aguilar, G. Flavanol-Enriched Cocoa Powder Alters the Intestinal Microbiota, Tissue and Fluid Metabolite Profiles, and Intestinal Gene Expression in Pigs. J. Nutr. 2016, 146, 673–680. [Google Scholar] [CrossRef]
  21. Magistrelli, D.; Zanchi, R.; Malagutti, L.; Galassi, G.; Canzi, E.; Rosi, F. Effects of Cocoa Husk Feeding on the Composition of Swine Intestinal Microbiota. J. Agric. Food Chem. 2016, 64, 2046–2052. [Google Scholar] [CrossRef]
  22. Anhê, F.F.; Varin, T.V.; Le Barz, M.; Desjardins, Y.; Levy, E.; Roy, D.; Marette, A. Gut Microbiota Dysbiosis in Obesity-Linked Metabolic Diseases and Prebiotic Potential of Polyphenol-Rich Extracts. Curr. Obes. Rep. 2015, 4, 389–400. [Google Scholar] [CrossRef]
  23. Walker, J.J.; Eckardt, P.; Aleman, J.O.; da Rosa, J.C.; Liang, Y.; Iizumi, T.; Etheve, S.; Blaser, M.J.; L Breslow, J.; Holt, P.R. The effects of trans-resveratrol on insulin resistance, inflammation, and microbiota in men with the metabolic syndrome: A pilot randomized, placebo-controlled clinical trial. J. Clin. Transl. Res. 2019, 4, 122–135. [Google Scholar]
  24. Halmos, E.E.; Christophersen, C.C.; Bird, A.A.; Shepherd, S.S.; Gibson, P.P.; Muir, J.J. Diets that differ in their FODMAP content alter the colonic luminal microEnvironironment. Gut 2015, 64, 93–100. [Google Scholar] [CrossRef]
  25. Halmos, E.E.; Christophersen, C.C.; Bird, A.A.; Shepherd, S.S.; Muir, J.J.; Gibson, P.P. Consistent Prebiotic Effect on Gut Microbiota With Altered FODMAP Intake in Patients with Crohn’s Disease: A Randomised, Controlled Cross-Over Trial of Well-Defined Diets. Clin. Transl. Gastroenterol. 2016, 7, e164. [Google Scholar] [CrossRef]
  26. Ramirez-Farias, C.; Slezak, K.; Fuller, Z.; Duncan, A.; Holtrop, G.; Louis, P. Effect of inulin on the human gut microbiota: Stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br. J. Nutr. 2009, 101, 541–550. [Google Scholar] [CrossRef]
  27. Ramnani, P.; Gaudier, E.; Bingham, M.; van Bruggen, P.; Tuohy, K.K.; Gibson, G.G. Prebiotic effect of fruit and vegetable shots containing Jerusalem artichoke inulin: A human intervention study. Br. J. Nutr. 2010, 104, 233–240. [Google Scholar] [CrossRef]
  28. Roshanravan, N.; Mahdavi, R.; Alizadeh, E.; Ghavami, A.; Rahbar Saadat, Y.; Mesri Alamdari, N.; Alipour, S.; Dastouri, M.R.; Ostadrahimi, A. The effects of sodium butyrate and inulin supplementation on angiotensin signaling pathway via promotion of Akkermansia muciniphila abundance in type 2 diabetes; A randomized, double-blind, placebo-controlled trial. J. Cardiovasc. Thorac. Res. 2017, 9, 183–190. [Google Scholar] [CrossRef]
  29. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.D.; Group, P. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009, 6, e1000097. [Google Scholar] [CrossRef]
  30. Stroup, D.F.; Berlin, J.J.; Morton, S.C.; Olkin, I.; Williamson, G.D.; Rennie, D.; Moher, D.; Becker, B.J.; Sipe, T.A.; Thacker, S.B. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2008, 283, 2008–2012. [Google Scholar] [CrossRef]
  31. Higgins, J.P.; Altman, D.G.; Gøtzsche, P.C.; Jüni, P.; Moher, D.; Oxman, A.D.; Savovic, J.; Schulz, K.F.; Weeks, L.; Sterne, J.A.; et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011, 343, d5928. [Google Scholar] [CrossRef]
  32. Benjamin, J.L.; Hedin, C.R.; Koutsoumpas, A.; Ng, S.C.; McCarthy, N.E.; Hart, A.L.; Kamm, M.A.; Sanderson, J.D.; Knight, S.C.; Forbes, A.; et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut 2011, 60, 923–929. [Google Scholar] [CrossRef]
  33. Blatchford, P.; Stoklosinski, H.; Eady, S.; Wallace, A.; Butts, C.; Gearry, R.; Gibson, G.; Ansell, J. Consumption of kiwifruit capsules increases Faecalibacterium prausnitzii abundance in functionally constipated individuals: A randomised controlled human trial. J. Nutr. Sci. 2017, 6, e52. [Google Scholar] [CrossRef]
  34. Clavel, T.; Fallani, M.; Lepage, P.; Levenez, F.; Mathey, J.; Rochet, V.; Sérézat, M.; Sutren, M.; Henderson, G.; Bennetau-Pelissero, C.; et al. Isoflavones and functional foods alter the dominant intestinal microbiota in postmenopausal women. J. Nutr. 2005, 135, 2786–2792. [Google Scholar] [CrossRef]
  35. Dao, M.M.; Everard, A.; Aron-Wisnewsky, J.; Sokolovska, N.; Prifti, E.; Verger, E.O.; Kayser, B.D.; Levenez, F.; Chilloux, J.; Hoyles, L.; et al. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: Relationship with gut microbiome richness and ecology. Gut 2016, 65, 426–436. [Google Scholar] [CrossRef]
  36. Dewulf, E.M.; Cani, P.D.; Claus, S.P.; Fuentes, S.; Puylaert, P.G.; Neyrinck, A.M.; Bindels, L.B.; de Vos, W.M.; Gibson, G.R.; Thissen, J.P.; et al. Insight into the prebiotic concept: Lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut 2013, 62, 1112–1121. [Google Scholar] [CrossRef]
  37. Fava, F.; Gitau, R.; Griffin, B.B.; Gibson, G.G.; Tuohy, K.K.; Lovegrove, J.J. The type and quantity of dietary fat and carbohydrate alter faecal microbiome and short-chain fatty acid excretion in a metabolic syndrome ’at-risk’ population. Int. J. Obes. (2005) 2013, 37, 216–223. [Google Scholar] [CrossRef]
  38. Fernando, W.W.; Hill, J.J.; Zello, G.G.; Tyler, R.R.; Dahl, W.W.; Van Kessel, A.A. Diets supplemented with chickpea or its main oligosaccharide component raffinose modify faecal microbial composition in healthy adults. Benef. Microbes 2010, 1, 197–207. [Google Scholar] [CrossRef][Green Version]
  39. Guadamuro, L.; Delgado, S.; Redruello, B.; Flórez, A.B.; Suárez, A.; Martínez-Camblor, P.; Mayo, B. Equol status and changes in fecal microbiota in menopausal women receiving long-term treatment for menopause symptoms with a soy-isoflavone concentrate. Front. Microbiol. 2015, 6, 777. [Google Scholar] [CrossRef]
  40. Hooda, S.; Boler, B.M.; Serao, M.C.; Brulc, J.M.; Staeger, M.A.; Boileau, T.W.; Dowd, S.E.; Fahey, G.C., Jr.; Swanson, K.S. 454 pyrosequencing reveals a shift in fecal microbiota of healthy adult men consuming polydextrose or soluble corn fiber. J. Nutr. 2012, 142, 1259–1265. [Google Scholar] [CrossRef]
  41. Hustoft, T.N.; Hausken, T.; Ystad, S.O.; Valeur, J.; Brokstad, K.; Hatlebakk, J.G.; Lied, G.A. Effects of varying dietary content of fermentable short-chain carbohydrates on symptoms, fecal microEnvironironment, and cytokine profiles in patients with irritable bowel syndrome. Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 2017, 29, e12969. [Google Scholar] [CrossRef]
  42. Lee, T.; Clavel, T.; Smirnov, K.; Schmidt, A.; Lagkouvardos, I.; Walker, A.; Lucio, M.; Michalke, B.; Schmitt-Kopplin, P.; Fedorak, R.; et al. Oral versus intravenous iron replacement therapy distinctly alters the gut microbiota and metabolome in patients with IBD. Gut 2017, 66, 863–871. [Google Scholar] [CrossRef]
  43. Li, Z.; Henning, S.M.; Lee, R.P.; Lu, Q.Y.; Summanen, P.H.; Thames, G.; Corbett, K.; Downes, J.; Tseng, C.H.; Finegold, S.M.; et al. Pomegranate extract induces ellagitannin metabolite formation and changes stool microbiota in healthy volunteers. Food Funct. 2015, 6, 2487–2495. [Google Scholar] [CrossRef]
  44. Majid, H.H.; Cole, J.; Emery, P.P.; Whelan, K. Additional oligofructose/inulin does not increase faecal bifidobacteria in critically ill patients receiving enteral nutrition: A randomised controlled trial. Clin. Nutr. (Edinb. Scotl.) 2014, 33, 966–972. [Google Scholar] [CrossRef]
  45. Medina-Vera, I.; Sanchez-Tapia, M.; Noriega-Lopez, L.; Granados-Portillo, O.; Guevara-Cruz, M.; Flores-López, A.; Avila-Nava, A.; Fernández, M.L.; Tovar, A.R.; Torres, N. A dietary intervention with functional foods reduces metabolic endotoxaemia and attenuates biochemical abnormalities by modifying faecal microbiota in people with type 2 diabetes. Diabetes Metab. 2019, 45, 122–131. [Google Scholar] [CrossRef]
  46. Moreno-Indias, I.; Sanchez-Alcoholado, L.; Perez-Martinez, P.; Andrés-Lacueva, C.; Cardona, F.; Tinahones, F.; Queipo-Ortuño, M.I. Red wine polyphenols modulate fecal microbiota and reduce markers of the metabolic syndrome in obese patients. Food Funct. 2016, 7, 1775–1787. [Google Scholar] [CrossRef]
  47. Most, J.; Penders, J.; Lucchesi, M.; Goossens, G.G.; Blaak, E.E. Gut microbiota composition in relation to the metabolic response to 12-week combined polyphenol supplementation in overweight men and women. Eur. J. Clin. Nutr. 2017, 71, 1040–1045. [Google Scholar] [CrossRef]
  48. Pinheiro, I.; Robinson, L.; Verhelst, A.; Marzorati, M.; Winkens, B.; den Abbeele, P.V.; Possemiers, S. A yeast fermentate improves gastrointestinal discomfort and constipation by modulation of the gut microbiome: Results from a randomized double-blind placebo-controlled pilot trial. BMC Complement. Altern. Med. 2017, 17, 441. [Google Scholar] [CrossRef]
  49. Tagliabue, A.; Ferraris, C.; Uggeri, F.; Trentani, C.; Bertoli, S.; de Giorgis, V.; Veggiotti, P.; Elli, M. Short-term impact of a classical ketogenic diet on gut microbiota in GLUT1 Deficiency Syndrome: A 3-month prospective observational study. Clin. Nutr. ESPEN 2017, 17, 33–37. [Google Scholar] [CrossRef]
  50. Wijayabahu, A.A.; Waugh, S.S.; Ukhanova, M.; Mai, V. Dietary raisin intake has limited effect on gut microbiota composition in adult volunteers. Nutr. J. 2019, 18, 14. [Google Scholar] [CrossRef]
  51. Xu, J.; Lian, F.; Zhao, L.; Zhao, Y.; Chen, X.; Zhang, X.; Guo, Y.; Zhang, C.; Zhou, Q.; Xue, Z.; et al. Structural modulation of gut microbiota during alleviation of type 2 diabetes with a Chinese herbal formula. ISME J. 2015, 9, 552–562. [Google Scholar] [CrossRef]
  52. Benus, R.F.; van der Werf, T.S.; Welling, G.W.; Judd, P.A.; Taylor, M.A.; Harmsen, H.J.; Whelan, K. Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects. Br. J. Nutr. 2010, 104, 693–700. [Google Scholar] [CrossRef]
  53. James, S.L.; Christophersen, C.T.; Bird, A.R.; Conlon, M.A.; Rosella, O.; Gibson, P.R.; Muir, J.G. Abnormal fibre usage in UC in remission. Gut 2015, 64, 562–570. [Google Scholar] [CrossRef]
  54. Vulevic, J.; Juric, A.; Tzortzis, G.; Gibson, G.G. A mixture of trans-galactooligosaccharides reduces markers of metabolic syndrome and modulates the fecal microbiota and immune function of overweight adults1–3. J. Nutr. 2013, 143, 324–331. [Google Scholar] [CrossRef]
  55. West, N.P.; Christophersen, C.T.; Pyne, D.B.; Cripps, A.W.; Conlon, M.A.; Topping, D.L.; Kang, S.; McSweeney, C.S.; Fricker, P.A.; Aguirre, D.; et al. Butyrylated starch increases colonic butyrate concentration but has limited effects on immunity in healthy physically active individuals. Exerc. Immunol. Rev. 2013, 19, 102–119. [Google Scholar]
  56. Bull, M.M.; Plummer, N.N. Part 1: The Human Gut Microbiome in Health and Disease. Integr. Med. 2014, 13, 17–22. [Google Scholar]
  57. Vyas, U.; Ranganathan, N. Probiotics, prebiotics, and synbiotics: Gut and beyond. Gastroenterol. Res. Pract. 2012, 2012, 872716. [Google Scholar] [CrossRef]
  58. Karlsson, F.H.; Tremaroli, V.; Nookaew, I.; Bergström, G.; Behre, C.J.; Fagerberg, B.; Nielsen, J.; Bäckhed, F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature 2013, 498, 99–103. [Google Scholar] [CrossRef]
  59. Vrieze, A.; Van Nood, E.; Holleman, F.; Salojärvi, J.; Kootte, R.S.; Bartelsman, J.F.; Dallinga-Thie, G.M.; Ackermans, M.T.; Serlie, M.J.; Oozeer, R.; et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 2012, 143, 913–916.e7. [Google Scholar] [CrossRef]
  60. Belzer, C.; Chia, L.W.; Aalvink, S.; Chamlagain, B.; Piironen, V.; Knol, J.; de Vos, W.M. Microbial Metabolic Networks at the Mucus Layer Lead to Diet-Independent Butyrate and Vitamin B12 Production by Intestinal Symbionts. MBio 2017, 8. [Google Scholar] [CrossRef]
  61. Chang, P.P.; Hao, L.; Offermanns, S.; Medzhitov, R. The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition. Proc. Natl. Acad. Sci. USA 2014, 111, 2247–2252. [Google Scholar] [CrossRef][Green Version]
  62. Furusawa, Y.; Obata, Y.; Fukuda, S.; Endo, T.A.; Nakato, G.; Takahashi, D.; Nakanishi, Y.; Uetake, C.; Kato, K.; Kato, T.; et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504, 446–450. [Google Scholar] [CrossRef]
  63. Kelly, C.J.; Zheng, L.; Campbell, E.L.; Saeedi, B.; Scholz, C.C.; Bayless, A.J.; Wilson, K.E.; Glover, L.E.; Kominsky, D.J.; Magnuson, A.; et al. Crosstalk between Microbiota-Derived Short-Chain Fatty Acids and Intestinal Epithelial HIF Augments Tissue Barrier Function. Cell Host Microbe 2015, 17, 662–671. [Google Scholar] [CrossRef][Green Version]
  64. Wang, H.; Hou, L.; Kwak, D.; Fassett, J.; Xu, X.; Chen, A.; Chen, W.; Blazar, B.R.; Xu, Y.; Hall, J.L.; et al. Increasing Regulatory T Cells With Interleukin-2 and Interleukin-2 Antibody Complexes Attenuates Lung Inflammation and Heart Failure Progression. Hypertension 2016, 68, 114–122. [Google Scholar] [CrossRef]
  65. De Vadder, F.; Kovatcheva-Datchary, P.; Goncalves, D.; Vinera, J.; Zitoun, C.; Duchampt, A.; Bäckhed, F.; Mithieux, G. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014, 156, 84–96. [Google Scholar] [CrossRef]
  66. Lukovac, S.; Belzer, C.; Pellis, L.; Keijser, B.J.; de Vos, W.M.; Montijn, R.C.; Roeselers, G. Differential modulation by Akkermansia muciniphila and Faecalibacterium prausnitzii of host peripheral lipid metabolism and histone acetylation in mouse gut organoids. MBio 2014, 5. [Google Scholar] [CrossRef]
  67. Lee, H.; Ko, G. Effect of metformin on metabolic improvement and gut microbiota. Appl. Environ. Microbiol. 2014, 80, 5935–5943. [Google Scholar] [CrossRef]
  68. Shin, N.R.; Lee, J.C.; Lee, H.Y.; Kim, M.S.; Whon, T.W.; Lee, M.S.; Bae, J.W. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 2014, 63, 727–735. [Google Scholar] [CrossRef]
  69. Everard, A.; Belzer, C.; Geurts, L.; Ouwerkerk, J.P.; Druart, C.; Bindels, L.B.; Guiot, Y.; Derrien, M.; Muccioli, G.G.; Delzenne, N.M.; et al. Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity. Proc. Natl. Acad. Sci. USA 2013, 110, 9066–9071. [Google Scholar] [CrossRef]
  70. Singh, R.K.; Chang, H.W.; Yan, D.; Lee, K.M.; Ucmak, D.; Wong, K.; Abrouk, M.; Farahnik, B.; Nakamura, M.; Zhu, T.H.; et al. Influence of diet on the gut microbiome and implications for human health. J. Transl. Med. 2017, 15. [Google Scholar] [CrossRef]
  71. Morrison, D.D.; Preston, T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016, 7, 189–200. [Google Scholar] [CrossRef][Green Version]
  72. Jardine, M. Nutrition Considerations for Microbiota Health in Diabetes. Diabetes Spectr. A Publ. Am. Diabetes Assoc. 2016, 29, 238–244. [Google Scholar] [CrossRef][Green Version]
  73. Liu, X.; Wu, Y.; Li, F.; Zhang, D. Dietary fiber intake reduces risk of inflammatory bowel disease: Result from a meta-analysis. Nutr. Res. 2015, 35, 753–758. [Google Scholar] [CrossRef]
  74. McRae, M.M. Dietary Fiber Intake and Type 2 Diabetes Mellitus: An Umbrella Review of Meta-analyses. J. Chiropr. Med. 2018, 17, 44–53. [Google Scholar] [CrossRef]
  75. Ismail, T.; Sestili, P.; Akhtar, S. Pomegranate peel and fruit extracts: A review of potential anti-inflammatory and anti-infective effects. J. Ethnopharmacol. 2012, 143, 397–405. [Google Scholar] [CrossRef]
  76. Medjakovic, S.; Jungbauer, A. Pomegranate: A fruit that ameliorates metabolic syndrome. Food Funct. 2013, 4, 19–39. [Google Scholar] [CrossRef]
  77. Franco, O.H.; Chowdhury, R.; Troup, J.; Voortman, T.; Kunutsor, S.; Kavousi, M.; Oliver-Williams, C.; Muka, T. Use of Plant-Based Therapies and Menopausal Symptoms: A Systematic Review and Meta-analysis. JAMA 2016, 315, 2554–2563. [Google Scholar] [CrossRef]
  78. Glisic, M.; Kastrati, N.; Gonzalez-Jaramillo, V.; Bramer, W.M.; Ahmadizar, F.; Chowdhury, R.; Danser, A.J.; Roks, A.J.; Voortman, T.; Franco, O.H.; et al. Associations between Phytoestrogens, Glucose Homeostasis, and Risk of Diabetes in Women: A Systematic Review and Meta-Analysis. Adv. Nutr. 2018, 9, 726–740. [Google Scholar] [CrossRef]
  79. Ozdal, T.; Sela, D.D.; Xiao, J.; Boyacioglu, D.; Chen, F.; Capanoglu, E. The Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on Bioaccessibility. Nutrients 2016, 8, 78. [Google Scholar] [CrossRef]
  80. David, L.A.; Maurice, C.F.; Carmody, R.N.; Gootenberg, D.B.; Button, J.E.; Wolfe, B.E.; Ling, A.V.; Devlin, A.S.; Varma, Y.; Fischbach, M.A.; et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature 2014, 505, 559–563. [Google Scholar] [CrossRef]
  81. Gomez, A.; Luckey, D.; Taneja, V. The gut microbiome in autoimmunity: Sex matters. Clin. Immunol. 2015, 159, 154–162. [Google Scholar] [CrossRef]
  82. Kaplan, H.; Hill, K.; Lancaster, J.; Hurtado, A.A. A theory of human life history evolution: Diet, intelligence, and longevity. Evol. Anthropol. Issues News Rev. 2000, 9, 156–185. [Google Scholar] [CrossRef]
  83. Zeevi, D.; Korem, T.; Zmora, N.; Israeli, D.; Rothschild, D.; Weinberger, A.; Ben-Yacov, O.; Lador, D.; Avnit-Sagi, T.; Lotan-Pompan, M.; et al. Personalized Nutrition by Prediction of Glycemic Responses. Cell 2015, 163, 1079–1094. [Google Scholar] [CrossRef][Green Version]
  84. Moen, B.; Berget, I.; Rud, I.; Hole, A.A.; Kjos, N.N.; Sahlstrom, S. Extrusion of barley and oat influence the fecal microbiota and SCFA profile of growing pigs. Food Funct. 2016, 7, 1024–1032. [Google Scholar] [CrossRef]
  85. Grundy, M.M.-L.; Lapsley, K.; Ellis, P.P. A review of the impact of processing on nutrient bioaccessibility and digestion of almonds. Int. J. Food Sci. Technol. 2016, 51, 1937–1946. [Google Scholar] [CrossRef][Green Version]
  86. Zinöcker, M.M.; Lindseth, I.I. The Western Diet-Microbiome-Host Interaction and Its Role in Metabolic Disease. Nutrients 2018, 10, 365. [Google Scholar] [CrossRef]
Nutrients 11 01565 g001 550
Figure 1. Flowchart of studies included in the current review.
Figure 1. Flowchart of studies included in the current review.
Nutrients 11 01565 g001
Table
Table 1. Descriptive Summary of Randomized Clinical Trials Investigating the Associations Between Dietary Interventions and Akkermansia Muciniphila.
Table 1. Descriptive Summary of Randomized Clinical Trials Investigating the Associations Between Dietary Interventions and Akkermansia Muciniphila.
Lead Author, Publication YearStudy DesignLocation/Age RangeIndividual Health StatusTotal ParticipantsSexPeriod of InterventionDietary Treatment CharacteristicsMain Findings
Intervention TypeControl Type
Blatchford P et al. 2017* [1]Randomized double-blind placebo-controlled cross-over trialNew Zealand/23–56Healthy participants with no clinical symptoms of constipation and functionally constipated participants29W and M4 weeks each intervention (2 weeks washout period between each intervention)ACTAZIN™ (600 mg/d) green kiwifruit extract low dose Placebo (isomalt coloured green 2400 mg/d)A. muciniphila was significantly more abundant in the functionally constipated group, but no effect of the interventions on A. muciniphila.
ACTAZIN™ (2400 mg/d) green kiwifruit extract high dose
Livaux™ (2400 mg/d) gold kiwifruit extract
Dao M et al. 2015 [13]Single-arm cross-over trialFrance/41.9 ± 12.3Overweight and obese participants49W and M12 weeksCaloric restriction diet (1200 kcal/d for W and 1500 kcal/d for M)Weight stabilization diet (prescribed individually by a dietitian)Caloric restriction diet: Subjects with A. muciniphila at or above the median had a decrease in abundance of A. muciniphila while in the group with A. muciniphila lower than median there was an increase. The difference was statistical significant.

Weight stabilization diet: In both subjects with A. muciniphila at or above and lower, there was a decrease in abundance of A. muciniphila with no difference between the groups.
Halmos EP et al. 2015* [16]Single-arm blinded randomized cross-over trialAustralia/18+Healthy participants and participants with irritable bowel syndrome33W and M6 weeksDiet low in FODMAPsDiet containing
FODMAP content of a typical Australian diet		Typical Australian diet increased absolute and relative abundance for mucus-associated A. muciniphila (p < 0.001).
Halmos EP et al. 2016* [17]Single-arm blinded randomized cross-over trialAustralia/18+Patients with clinically quiescent Crohn’s disease9W and M6 weeksDiet low in FODMAPsDiet containing
FODMAP content of a typical Australian diet		Relative abundance was higher for mucus-associated A. muciniphila during the Australian compared with low FODMAP diet (p = 0.016).
Hooda S et al. 2012* [6]Randomized double-blind placebo-controlled cross-over trialUSA/27.5 ± 4.33Healthy participants25M9 weeksPolydextrose (PDX) (7 g, 3 times per day)Placebo (no supplemental fiber control (NFC) (0 g, 3 times per day))A. muciniphila was greater after PDX intake than after the NFC or SCF treatment (p < 0.05).
Soluble corn fiber (SCF) (7 g, 3 times per day)
James SL et al. 2015* [54]Randomized single-blind cross-over trialAustralia/18–72Patients with UC in remission and healthy subjects29W and M8 weeks‘Low resistant starch (RS)/wheat bran (WB)’ foods containing 2–5 g RS and
2–5 g WB fibre per day		NAPatients with UC had a lower abundance of A. muciniphila. For both cohorts, increasing the intake of RS/WB gave no indication of changes in relative or absolute abundance.
‘High RS/WB’ foods containing 15 g
RS and 12 g WB fibre per day
Li Z et al. 2015 [20]Single-arm trialUSA/28.9 ± 8Healthy volunteers 20W and M4 weeksPomegranate extract
(1000 mg)		NAThe data were not shown for the overall population. A. muciniphila was 33 (at baseline) and 47 fold (after 4 weeks) higher in stool samples of Urolithin A producers compared to non-producers.
Medina-Vera I et al. 2019* [9]Randomized, double-blind placebo-controlled trialMexico/30–60Patients with Type 2 Diabetes81W and M3 monthsA reduced-energy diet with a dietary portfolio (DP) (14 g of dehydrated nopal, 4 g of chia seeds, 30 g of soy protein and 4 g of inulin)Placebo (28 g of calcium caseinate and 15 g of maltodextrin)DP consumption increased levels of A. muciniphila by approximately 125%.
Pinheiro I et al. 2017 [11]Randomized, double-blind placebo-controlled trialBelgium/20–69Healthy with reduced bowel movements and other symptoms of GI discomfort stratified in severe and moderate80W and M6 weeksEpiCor fermentate (500 mg/d)Placebo (maltodextrin (500 mg/d))Significant relative increase of A. muciniphila in the moderate GI discomfort symptoms group at visit week 3 (p = 0.0001) and visit week 6 (p = 0.036).
Roshanravan N et al. 2017 [25]Randomized, double-blind placebo-controlled trialIran/30–55Overweight and obese diabetes patients60W and M6 weeksGroup A: Butyrate group (600 mg/d sodium butyrate + inulin placebo)Butyrate + inulin placebo (6
starch capsules (100 mg) and 10 g of starch powder)		The percentage changes of A. muciniphila abundance indicated a significant increase in group taking sodium butyrate and inulin (group A and B) in comparison with the placebo group (p < 0.05). A non-significant rise in this bacterium concentration was seen after supplementation with both sodium butyrate and inulin (group C).
Group B: inulin group (10 g/d inulin powder + butyrate placebo)
Group C: butyrate + inulin group (600 mg/d sodium butyrate + 10 g/d inulin powder)
Walker JM et al. 2019 [27]Randomized, double-blind placebo-controlled trialUSA/30–70Obese insulin resistant subjects with metabolic syndrome28aM5 weeksResveratrol (500 mg Mega-RES 99% capsules twice daily)Placebo (two 500 mg placebo capsules twice daily)Overall, there was no difference. However, when split by ethnicity, resveratrol administration to Caucasian subjects led to an increase in A. muciniphila compared to the non-Caucasians.
* Studies examining both A. Muciniphila and F. Prausnitzii. FODMAPs Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols; FOS fructo-oligosaccharides; GI gastrointestinal; M men; NA not applicable; UC ulcerative colitis; W women. a Stool samples collected in 16 subjects.
Table
Table 2. Descriptive Summary of Randomized Clinical Trials Investigating the Associations Between Dietary Interventions and Faecalibacterium prausnitzii.
Table 2. Descriptive Summary of Randomized Clinical Trials Investigating the Associations Between Dietary Interventions and Faecalibacterium prausnitzii.
Lead Author, Publication YearStudy DesignLocation/Age RangeIndividual Health StatusTotal ParticipantsSexPeriod of InterventionDietary Treatment CharacteristicsMain Findings
Intervention TypeControl Type
Benjamin JL et al. 2011 [12]Randomized double-blinded placebo-controlled trialUK/39.5 ± 14.4Patients with Crohn’s disease103M4 weeksNormal diet supplemented with 15 g/day FOS, comprising fructose polymers of differing chain lengthsPlacebo (maltodextrin 15 g/day)No significant differences between patients in the FOS and placebo group at week 4 (p = 0.95).
Benus RFJ et al. 2010 [52]Randomized double-blinded cross-over trialUK/21–34Healthy14W and M4 weeksA formula supplemented
with dietary fibre (14 g/l) consisting of pea fibre and fructo-oligosaccharides		NAThere were large and statistically significant reductions in the numbers of the F. prausnitzii group during both the fibre-free and fibre-supplemented diets. No differences between the fibre-free and fibre-supplemented diet (p = 0.23).
A fibre-free enteral formula
Blatchford P et al. 2017* [1]Randomized double-blind placebo-controlled cross-over trialNew Zealand/23–56Healthy participants who had no clinical symptoms of constipation and functionally constipated participants29/W and MW and M4 weeks each intervention (2 weeks washout period between each intervention)ACTAZIN™ L (600 mg/d)Placebo (isomalt coloured green 2400 mg/d)F. prausnitzii abundance significantly increased from 3.4 to 7.0% following Livaux™ supplementation in the functionally constipated group (p = 0.024).
ACTAZIN™ H (2400 mg/d)
Livaux™ (2400 mg/d)
Clavel T et al. 2005 [2]Randomized double-blind placebo-controlled trialFrance/60.4 ± 7.1Postmenopausal women39W30 daysProbiotic group: isoflavones (100 mg/d) + B. animalis DN-173 010Placebo (isoflavones 100 mg/d)Bacterial percentages for F. prausnitzii subgroup decreased significantly in control subjects compared to the probiotic and prebiotic group (p = 0.034).
Prebiotic group: isoflavones (100 mg/d) + FOS (7 g/d)
Dewulf EM et al. 2012 [3]Double-blind placebo-controlled trialBelgium/
47.5 ± 8.5		Obese30W3 monthsITF prebiotics (Synergy 1, namely, inulin/oligofructose 50/50 mix)Placebo (maltodextrin)Treatment with ITF prebiotics, but not the placebo, led to an increase in F. prausnitzii.
Fava F et al. 2013 [14]Five-arm parallel, placebo-controlled, single-blind studyUK/56.0 ± 9.5Individuals at increased risk of metabolic syndrome88W and M24 weeksHigh SFA dietNANumbers of F. prausnitzii increased after intervention with high CHO and low GI (p = 0.022) and high SFA (p = 0.018) diet compared to baseline.
High MUFA/high GI
High MUFA/Low GI
High CHO/High GI
High CHO/Low GI
Fernando WMU et al. 2010 [4]Randomized cross-over trialCanada/25.6 ± 8.7Healthy12W and M9 weeksControl diet + 5 g/d raffinoseControl dietF. prausnitzii was more abundant in the raffinose diet and the chickpea diet compared to the control diet.
Control diet + 200 g/d canned chickpea
Guadamuro L et al. 2015 [15]Single-arm trialSpain/48–61Menopausal women with no chronic disease16W24 weeksOne tablet isoflavoneconcentrate (80 mg) per dayNAThere was an increase in the intensity of F. prausnitzii.
Halmos EP et al. 2015* [16]Single-arm blinded randomized cross-over trialAustralia/18+Irritable bowel syndrome and healthy individuals33W and M6 weeksDiet low in FODMAPsDiet containing
FODMAP content of a typical Australian diet		Low FODMAP diet reduced total bacterial abundance, but did not impact relative abundance of F. prausnitzii.
Halmos EP et al. 2016* [17]Single-arm blinded randomized cross-over trialAustralia/18+Patients with clinically quiescent Crohn’s disease9W and M6 weeksDiet low in FODMAPsDiet containing
FODMAP content of a typical Australian diet		No significant difference in F. prausnitzii between the two diets.
Hooda S et al. 2012* [6]Randomized double-blind placebo-controlled cross-over trialUSA/27.5 ± 4.33Healthy25M9 weeksPolydextrose (PDX) (7 g, 3 times per day)Placebo: no supplemental fiber control (NFC) (0 g, 3 times per day)F. prausnitzii was greater in participants when they consumed PDX or SCF than when they consumed NFC (p < 0.05).
Soluble corn fiber (SCF) (7 g, 3 times per day)
Hustoft TN et al. 2016 [7]Randomized double-blind placebo-controlled cross-over trialNorway/18–52Diarrhea-predominant or mixed irritated bowel syndrome20W and M10 days each intervention (3 weeks washout period)Fructo-oligosaccharides (FOS) 16 g/dPlacebo: Maltodextrin 16 g/dTen days of FOS supplementation increased the level of F. prausnitzii.
James SL et al. 2015* [54]Randomized single-blind cross-over trialAustralia/18–72Patients with UC in remission and healthy subjects29W and M8 weeks‘Low resistant starch (RS)/wheat bran (WB)’ foods containing 2–5 g RS and
2–5 g WB fibre per day		NAFor both cohorts, increasing the intake of RS/WB gave no indication of changes in relative or absolute abundance in F. prausnitzii.
‘High RS/WB’ foods containing 15 g
RS and 12 g WB fibre per day
Lee T et al. 2017 [19]Randomized, double-blind placebo-controlled trialCanada/18+Iron deficient Inflammatory bowel disease patients72W and M12 weeksOral iron sulfate 300 mg, tablet, twice a dayIron sucrose, 300 mg, intravenous, three or four/dayLower abundance of F. prausnitzii after oral iron therapy compared to intravenous iron therapy (p = 0.009).
Majid HA et al. 2014 [8]Multi-centre, randomized double-blind controlled trialUK/70.8 ± 9.7Patients from the ICU starting exclusive nasogastric enteral nutrition22W and MUp to 14 daysOligofructose/inulin 7 g/dPlacebo: maltodextrin 7 g/dThere were significantly lower concentrations of F. prausnitzii in patients receiving additional oligofructose/inulin (p = 0.01).
Medina-Vera I et al. 2019* [9]Single-centre randomized, controlled, double-blind parallel-group trialMexico/30–60Patients with Type 2 Diabetes81W and M3 monthsA reduced-energy diet with a dietary portfolio (DP) comprising 14  g of dehydrated nopal, 4 g of chia seeds, 30 g of soy protein and 4 g of inulinPlacebo, comprising of 28 g of calcium caseinate and 15 g of maltodextrin.Dietary intervention with functional foods significantly modified faecal microbiota compared with placebo. DP consumption for 12 weeks increased levels of F. prausnitzii by approximately 34%.
Moreno-Indias I et al. 2016 [21]Randomized, cross-over controlled trialSpain/45–50Metabolic syndrome and healthy individuals20M10 weeks (75 days)Red wine, 272 mL/dayDe-alcoholized (no ethanol) red wine, 272 mL/datIn metabolic syndrome patients, there was a significant increase of F. prausnitzii, after the red wine and de-alcoholized red wine intake periods compared to baseline. In the healthy group, a significant increase in the number of F. prausnitzii through the intervention period was observed.
Most J et al. 2017 [10]Randomized double-blind placebo-controlled trialThe Netherlands/20–50Obese42W and M12 weeksA combination of epigallocatechin-3-gallate (EGCG) and resveratrol (RES) supplements (EGCG + RES; 282 and 80 mg/day, respectively)Placebo (partly hydrolyzed microcrystalline cellulose-filled supplements)EGCG+RES supplementation significantly decreased Bacteroidetes and tended to reduce F. prausnitzii in men (p = 0.05 and p = 0.10, respectively) but not in women (P = 0.15 and P = 0.77, respectively).
Ramirez-Farias C et al. 2008 [23]Randomized, cross-over trialUK/38.1 ± 2.43Healthy adults12W and M3 weeksInulin–oligofructose, 5 g, twice dailyDid not consume any supplementF. prausnitzii exhibited a significant increase after intervention (p = 0.019).
Ramnani P et al. 2010 [24]Three-arm parallel, placebo-controlled, double-blind studyUK/18–50Healthy adults60W and M3 weeks intervention (3 weeks washout period)Jerusalem artichoke (JA) inulin- predominantly made of pear-carrot-sea buckthorn and JA juices or purées (PCS); two 100 mL shots per dayPlacebo: Water-based preparation with added sugar, thickened and flavoured with blood orange, carrot and raspberry extracts and flavours (but no juice or purees)No significant differences during the intervention and washout period.
JA inulin- predominantly made of plum-pear-beetroot and JA juices or purées (PPB); Two 100 mL shots per day
Tagliabue A et al. 2017 [26]Single-arm trialUSA/18–34Glucose Transporter 1 Deficiency Disorder (GLUT1-DS) patients6W and M12 weeksKetogenic diet including a minimum of 0.8–1 gram per kilogram of body weight of protein from animal sources (e.g., eggs, milk, meat, poultry and fish)NAThere was no statistical significant difference.
Vulevic J et al. 2013 [55]Randomized double-blind placebo-controlled cross-over trialUK/45.2 ± 11.9Overweight subjects predisposed to the development of metabolic syndrome45W and M12 weeks each intervention (4 week washout period)Bi2muno (B-GOS)Placebo (maltodextrin)The two dietary interventions had no significant effects on counts of total bacteria and F. prausnitzii cluster during the study.
West NP et al. 2013 [56]Randomized double-blind controlled trialAustralia/37.4 ± 8.4Healthy active cyclists41W and M28 daysIngestion of 40 g/day of butyrylated high amylose maize starch (HAMSB)Low amylose maize starch (LAMS)There were relative greater increases in faecal F. prausnitzii (5.1-fold; p < 0.01) in the HAMSB group.
Wijayabahu AT et al. 2019 [28]Single-arm trialUSA/18–59Healthy individuals13W and M2 weeksSun-dried raisins:
Three servings per day; one serving contained 28.3 g raisins and 2 grams of dietary fiber		NAF. prausnitzii significantly
increased after the first week of raisin intake and this increase continued during the second week of raisin consumption (p < 0.05).
Xu J et al. 2015 [29]Randomized, double-blind placebo-controlled clinical trialChina/8.5 ± 2.6Recently diagnosed type-2 diabetes patients187W and M12 weeksLow dose of Gegen Qinlian DecoctionPlaceboAll three doses of GQD treatment significantly enriched F. prausnitzii compared with baseline.
Medium dose of Gegen Qinlian Decoction
High dose of Gegen Qinlian Decoction
* Studies examining both A. Muciniphila and F. Prausnitzii. CHO Carbohydrate; GI Glycemic index; FODMAPs Fermentable Oligosaccharides, Disaccharides, Monosaccharides and Polyols; FOS fructo-oligosaccharides; ICU intensive care unit; ITF Inulin-type fructans; M men; MUFA monosaturated fat; SFA Saturated fatty acids; UC ulcerative colitis; W women.

Share and Cite

MDPI and ACS Style

Verhoog, S.; Taneri, P.E.; Roa Díaz, Z.M.; Marques-Vidal, P.; Troup, J.P.; Bally, L.; Franco, O.H.; Glisic, M.; Muka, T. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients 2019, 11, 1565. https://doi.org/10.3390/nu11071565

AMA Style

Verhoog S, Taneri PE, Roa Díaz ZM, Marques-Vidal P, Troup JP, Bally L, Franco OH, Glisic M, Muka T. Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review. Nutrients. 2019; 11(7):1565. https://doi.org/10.3390/nu11071565

Chicago/Turabian Style

Verhoog, Sanne, Petek Eylul Taneri, Zayne M. Roa Díaz, Pedro Marques-Vidal, John P. Troup, Lia Bally, Oscar H. Franco, Marija Glisic, and Taulant Muka. 2019. "Dietary Factors and Modulation of Bacteria Strains of Akkermansia muciniphila and Faecalibacterium prausnitzii: A Systematic Review" Nutrients 11, no. 7: 1565. https://doi.org/10.3390/nu11071565

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop